NanoViricides, Inc.
General ticker "NNVC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $21.9M (TTM average)
NanoViricides, Inc. follows the US Stock Market performance with the rate: 7.2%.
Estimated limits based on current volatility of 5.9%: low 1.55$, high 1.73$
Factors to consider:
- Total employees count: 3 as of 2008
- Top business risk factors: Operational and conduct risks, Need for additional capital, Regulatory and compliance, Limited operating history and clinical trial experience, Third-party risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [0.97$, 2.29$]
- 2026-06-30 to 2027-06-30 estimated range: [1.01$, 2.34$]
Financial Metrics affecting the NNVC estimates:
- Positive: with PPE of -2.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.27 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term NNVC quotes
Long-term NNVC plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.94MM | $8.52MM | $9.59MM |
| Operating Income | $-8.94MM | $-8.52MM | $-9.59MM |
| Non-Operating Income | $0.35MM | $0.22MM | $0.12MM |
| Interest Expense | $0.00MM | $0.05MM | $0.00MM |
| R&D Expense | $6.39MM | $5.44MM | $5.55MM |
| Income(Loss) | $-8.59MM | $-8.29MM | $-9.47MM |
| Net Income(Loss)* | $-8.59MM | $-8.29MM | $-9.47MM |
| Stockholders Equity | $14.87MM | $11.46MM | $7.52MM |
| Assets | $16.90MM | $12.82MM | $8.82MM |
| Operating Cash Flow | $-5.67MM | $-6.32MM | $-8.48MM |
| Capital expenditure | $0.15MM | $0.16MM | $0.06MM |
| Investing Cash Flow | $-0.15MM | $-0.16MM | $-0.06MM |
| Financing Cash Flow | $-0.09MM | $3.12MM | $5.30MM |
| Earnings Per Share** | $-0.74 | $-0.70 | $-0.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.